Generic Name: sacituzumab govitecan

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Immunomedics

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Trodelvy is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer and advanced bladder (urothelial) cancer.

General Info

Trodelvy, sacituzumab

Trodelvy consists of a monoclonal antibody that targets Trop-2, a protein found in more than 90% of triple-negative breast tumors. The antibody delivers an active form of the chemotherapy drug irinotecan.

The Phase II IMMU-132-01 trial showed that Trodelvy shrank tumors in a third of people with triple-negative breast cancer who had received at least two prior treatments for metastatic disease. In the TROPHY trial, the overall response rate was 28%. Trodelvy was first approved in April 2020.


Dosing Info:

Trodelvy is administered by IV infusion on days 1 and 8 of a 21-day treatment cycle.

Side Effects

Common adverse events reactions include nausea, neutropenia (low white blood cell count), diarrhea, fatigue, anemia, vomiting, abdominal pain, decreased appetite, constipation, hair loss and rash. Potential serious side effects may include severe neutropenia that can lead to and infections, severe diarrhea, severe nausea and hypersensitivity reactions. Trodelvy can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: April 13, 2021